Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q4 FY23 results · Jan–Mar 2023
Panacea Biotec reported revenue from operations of ₹128.93 crore (down 8.4% from Q4 FY22) and net loss of ₹12.68 crore for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 128.93 | 140.73 | −8.4% | 115.20 | +11.9% |
| Other income | 15.06 | 4.05 | +271.9% | 13.94 | +8.0% |
| Total income | 143.99 | 144.78 | −0.5% | 129.14 | +11.5% |
| Profit before tax | 18.21 | 1,608.26 | −98.9% | 22.44 | −18.9% |
| Net profit for the period | (12.68) | 1,237.47 | Turned loss | 19.37 | Turned loss |
| EPS, basic (₹) | (2.07) | 202.03 | Turned loss | 3.16 | Turned loss |
| Net margin (%) | -9.8 | 879.3 | 16.8 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 75.02 | 41.50 | +80.8% | 71.97 | +4.2% |
| Other income | 10.27 | 2.57 | +299.6% | 9.71 | +5.8% |
| Total income | 85.29 | 44.07 | +93.5% | 81.68 | +4.4% |
| Profit before tax | 5.10 | (25.31) | Turned profit | 13.24 | −61.5% |
| Net profit for the period | (19.69) | (25.31) | Loss narrowed | 13.24 | Turned loss |
| EPS, basic (₹) | (3.21) | (4.13) | Loss narrowed | 2.16 | Turned loss |
| Net margin (%) | -26.2 | -61.0 | 18.4 |
Consolidated
- Filed with BSE
- 31 May 2023, 12:40 IST
- Board meeting
- 30 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 May 2023, 12:40 IST
- Board meeting
- 30 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE